Structure Therapeutics Inc. Payments of Debt Issuance Costs
Structure Therapeutics Inc. (GPCR) reported Payments of Debt Issuance Costs of $37.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-06
- Structure Therapeutics Inc. payments of debt issuance costs for the quarter ending 2026-06-30 was $0.00.
- Structure Therapeutics Inc. payments of debt issuance costs for the quarter ending 2026-03-31 was $37.00K.
- Structure Therapeutics Inc. payments of debt issuance costs for the quarter ending 2025-12-31 was $1.25M.
- Structure Therapeutics Inc. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Structure Therapeutics Inc. payments of debt issuance costs for fiscal 2025 was $2.02M, a 12.47% increase from fiscal 2024.
- Structure Therapeutics Inc. payments of debt issuance costs for fiscal 2024 was $1.80M, a 91.67% decline from fiscal 2023.
- Structure Therapeutics Inc. payments of debt issuance costs for fiscal 2023 was $21.57M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $37.00K 10-Q · filed 2026-08-06 | $1.29M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2026-03-31 | $37.00K 10-Q · filed 2026-05-07 | $1.29M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.02M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $770.00K 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.15M derived: sum of 2 quarters · filed 2026-02-26 | $1.74M derived: sum of 3 quarters · filed 2026-02-26 | $1.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.74M derived: sum of 2 quarters · filed 2025-11-06 | $1.80M 10-Q · filed 2025-11-06 | $20.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $589.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $642.00K 10-Q · filed 2025-08-06 | $19.13M derived: sum of 3 quarters · filed 2026-02-26 | $19.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $53.00K 10-Q · filed 2025-05-08 | $18.54M derived: sum of 2 quarters · filed 2026-02-26 | $18.54M derived: sum of 3 quarters · filed 2026-02-26 | $19.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $18.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.49M derived: sum of 2 quarters · filed 2026-02-26 | $18.96M derived: sum of 3 quarters · filed 2026-02-26 | $21.57M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $476.00K derived: sum of 2 quarters · filed 2024-11-13 | $3.08M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.08M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $2.60M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $288.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $749.00K derived: sum of 2 quarters · filed 2023-11-17 | $2.20M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $461.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $1.91M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | $1.45M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |